Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Dec 22;13(1):1.
doi: 10.3390/toxins13010001.

Engineering Botulinum Neurotoxins for Enhanced Therapeutic Applications and Vaccine Development

Christine Rasetti-Escargueil  1 , Michel R Popoff  1
Affiliations
Review

Engineering Botulinum Neurotoxins for Enhanced Therapeutic Applications and Vaccine Development

Christine Rasetti-Escargueil et al. Toxins (Basel). .

Abstract

Botulinum neurotoxins (BoNTs) show increasing therapeutic applications ranging from treatment of locally paralyzed muscles to cosmetic benefits. At first, in the 1970s, BoNT was used for the treatment of strabismus, however, nowadays, BoNT has multiple medical applications including the treatment of muscle hyperactivity such as strabismus, dystonia, movement disorders, hemifacial spasm, essential tremor, tics, cervical dystonia, cerebral palsy, as well as secretory disorders (hyperhidrosis, sialorrhea) and pain syndromes such as chronic migraine. This review summarizes current knowledge related to engineering of botulinum toxins, with particular emphasis on their potential therapeutic applications for pain management and for retargeting to non-neuronal tissues. Advances in molecular biology have resulted in generating modified BoNTs with the potential to act in a variety of disorders, however, in addition to the modifications of well characterized toxinotypes, the diversity of the wild type BoNT toxinotypes or subtypes, provides the basis for innovative BoNT-based therapeutics and research tools. This expanding BoNT superfamily forms the foundation for new toxins candidates in a wider range of therapeutic options.

Keywords: Clostridium botulinum; botulinum neurotoxin; recombinant toxin; therapeutic application; toxin engineering.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Summary of the BoNTs engineering opportunities.
See this image and copyright information in PMC

References

    1. Cherington M. Botulism: Update and review. Semin. Neurol. 2004;24:155–163. doi: 10.1055/s-2004-830901. - DOI - PubMed
    1. Rossetto O., Seveso M., Caccin P., Schiavo G., Montecucco C. Tetanus and botulinum neurotoxins: Turning bad guys into good by research. Toxicon. 2001;39:27–41. doi: 10.1016/S0041-0101(00)00163-X. - DOI - PubMed
    1. Rigoni M., Caccin P., Johnson E.A., Montecucco C., Rossetto O. Site-directed mutagenesis identifies active-site residues of the light chain of botulinum neurotoxin type A. Biochem. Biophys. Res. Commun. 2001;288:1231–1237. doi: 10.1006/bbrc.2001.5911. - DOI - PubMed
    1. Schiavo G., Matteoli M., Montecucco C. Neurotoxins affecting neuroexocytosis. Physiol. Rev. 2000;80:717–766. doi: 10.1152/physrev.2000.80.2.717. - DOI - PubMed
    1. Dong M., Masuyer G., Stenmark P. Botulinum and Tetanus Neurotoxins. Annu. Rev. Biochem. 2019;88:811–837. doi: 10.1146/annurev-biochem-013118-111654. - DOI - PMC - PubMed

MeSH terms